SMART DRUG DELIVERY PLATFORM BASED ON CELL-DERIVED VESICLES
At MDimune, we are passionate about changing the world by developing innovative therapeutics.
Anti-cancer & CNS (including Rare disease)
Global Collaborations
Gene Therapy (mRNA, siRNA, miRNA, etc.)
PIDO (Platform Inside Development Outside)
Promotion of business development through cooperation with partners Multiple platform royalties
BioDrone® Platform based externally parallel processing of multiple pipelines
BioDrone Award (domestic) Global platform technologies (Targeting, CNS, etc.)
PIDO
(Platform Inside,
Development Outside)
Customized CDVs therapeutics optimized for various diseases and targets
Based on extensive global network in the clinical and manufacturing fields, MDimune handles multiple pipelines with reduced risks and minimized resources through external collaborations
Dr. Mario GimonaㅣProfessor, Paracelsus Medical University Dr. Eva RhodeㅣProfessor, Paracelsus Medical University Jin-Keon Pai, Ph.D.ㅣCEO, PAIJIN BioScience Inc. Minhyo Seo, Ph.D.ㅣVice President of R&D, Samyang Biopharm Corp.
K-BIO HEALTH OSONG Medical Innovation Foundation, QuBEST BIO, Biotoxtech, Axis Bio (UK)
Paracelsus Medical University, Stratec, L****, Celonic, Cytiva
Ildong Pharmaceutical, REYON Pharmaceutical, Asan Medical Center, POSTECH (Pohang University of Science and Technology), Inha University, Konkuk University, Korea University, The Catholic University of Korea
L**** (Switzerland), E****** (France), ExonanoRNA (US), Evercyte (Austria), Navigo Proteins (Germany), Vect-Horus (France)
MEDITIP, MJ International Patent Law Firm, JUNGJIN Intellectual Property Law Firm, PharmaVentures